- Stocks
- Healthcare
- NASDAQ: RGEN

Price (delayed)

$215.47

Market cap

$11.34B

P/E Ratio

259.6

Dividend/share

N/A

EPS

$0.83

Enterprise value

$11.06B

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in

The company's net income has surged by 87% YoY and by 42% QoQ

RGEN's EPS has surged by 63% year-on-year and by 43% since the previous quarter

The stock's P/E is 110% above its 5-year quarterly average of 123.8 and 27% above its last 4 quarters average of 203.9

RGEN's quick ratio is down by 18% year-on-year and by 13% since the previous quarter

What are the main financial stats of RGEN

Market
Valuations
Earnings

Shares outstanding

52.62M

Market cap

$11.34B

Enterprise value

$11.06B

Price to earnings (P/E)

259.6

Price to book (P/B)

10.06

Price to sales (P/S)

34.61

EV/EBIT

181.9

EV/EBITDA

127.91

EV/Sales

33.8

Revenue

$327.09M

EBIT

$60.78M

EBITDA

$86.44M

Free cash flow

$43.67M

Per share
Balance sheet
Liquidity

EPS

$0.83

Free cash flow per share

$0.83

Book value per share

$21.43

Revenue per share

$6.22

TBVPS

$14.82

Total assets

$1.48B

Total liabilities

$351.45M

Debt

$271.78M

Equity

$1.12B

Working capital

$645.74M

Debt to equity

0.24

Current ratio

13.67

Quick ratio

11.95

Net debt/EBITDA

-3.26

Margins
Efficiency
Dividend

EBITDA margin

26.4%

Gross margin

57.6%

Net margin

13.4%

Operating margin

17.8%

Return on assets

3.1%

Return on equity

4%

Return on invested capital

14.4%

Return on capital employed

4.3%

Return on sales

18.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Repligen stock price performed over time

Intraday

1.52%

1 week

3.41%

1 month

16.09%

1 year

116.34%

YTD

12.44%

QTD

12.44%

How have Repligen's revenue and profit performed over time

Revenue

$327.09M

Gross profit

$188.49M

Operating income

$58.3M

Net income

$43.83M

Gross margin

57.6%

Net margin

13.4%

The company's net income has surged by 87% YoY and by 42% QoQ

The operating income has soared by 53% YoY and by 29% from the previous quarter

The net margin has grown by 44% YoY and by 31% from the previous quarter

RGEN's gross profit is up by 35% YoY and by 10% QoQ

What is Repligen's growth rate over time

What is Repligen stock price valuation

P/E

259.6

P/B

10.06

P/S

34.61

EV/EBIT

181.9

EV/EBITDA

127.91

EV/Sales

33.8

The stock's P/E is 110% above its 5-year quarterly average of 123.8 and 27% above its last 4 quarters average of 203.9

RGEN's EPS has surged by 63% year-on-year and by 43% since the previous quarter

The P/B is 105% more than the 5-year quarterly average of 4.9 and 83% more than the last 4 quarters average of 5.5

Repligen's equity has increased by 8% YoY and by 2.3% QoQ

RGEN's P/S is 156% above its 5-year quarterly average of 13.5 and 75% above its last 4 quarters average of 19.8

The revenue has grown by 29% YoY and by 8% from the previous quarter

How efficient is Repligen business performance

RGEN's ROA is up by 41% since the previous quarter and by 35% year-on-year

The return on equity rose by 38% since the previous quarter and by 33% year-on-year

The ROIC has grown by 32% from the previous quarter but it has contracted by 25% YoY

RGEN's return on sales is up by 28% year-on-year and by 27% since the previous quarter

What is RGEN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for RGEN.

How did Repligen financials performed over time

RGEN's quick ratio is down by 18% year-on-year and by 13% since the previous quarter

Repligen's current ratio has decreased by 15% YoY and by 12% QoQ

The debt is 76% less than the equity

Repligen's equity has increased by 8% YoY and by 2.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.